Despite the rarity of each disease, rare diseases affect many patients worldwide.
There are more than 7,000 known rare diseases. Most of them are chronic, debilitating, or even life-threatening. More than half affect children. These diseases are characterized by a broad diversity of disorders and symptoms that vary not only from disease to disease, but also from patient to patient.
Rare diseases affect approximately 300 million patients worldwide. Due to unspecific symptoms and suboptimal awareness, the journey to the right diagnosis takes on average 6 to 8 years and all too often several mis-diagnoses unfortunately occur along the way. Shortening this diagnostic journey can improve quality of life, help patients and their families to understand their disease, and avoid unnecessary interventions. Earlier diagnosis is also crucial in providing more time for efficacious therapeutic interventions before irreversible damage – and working in this area with healthcare professionals is a core responsibility for Swixx.
The Rare diseases therapeutic area is a heritage focus of Swixx BioPharma. At Swixx we are proud to emphasize that our company enables the treatment of a large number of rare diseases - almost twenty. Swixx experts have extensive knowledge and a long-term history of achieving successful results in enabling patients’ access to the modern medicines of our partners, helping them live better lives. Swixx partners with the following innovative companies in this therapeutic area: AstraZeneca/Alexion, BioCryst, Blueprint Medicines, Ipsen, Jazz Pharmaceuticals, Kyowa Kirin, Otsuka, PTC and Sanofi.
At Swixx, patient care is at the heart of what we do. We see ourselves and aspire to be patients’ reliable partners throughout the healthcare cycle, by supporting education and diagnosis as well as helping the local healthcare community achieve better access to our partners' innovative medicines. In this journey, we strive to support the patient community through numerous partnerships.
Facing and coping with a rare diagnosis can be challenging for patients and their caregivers. Through Swixx’s project called “My Rare Disease Journey,” we tried to showcase rare disease patients’ personal experiences, views and insights. We were privileged to collaborate with several Patient Advocacy Organizations – as part of their effort to raise awareness, understanding and early diagnosis of rare diseases.
I am Indrek, a 42-year-old man from Estonia, and my life has been a constant battle against serious diseases. At the age of 17, I was diagnosed with lymphoma, plunging me into five years of facing death repeatedly. While I emerged declared “healthy” in my early twenties, the lack of strength prevented me from rising to my feet. Little did I know that my struggles were far from over.
Every day I hoped that it would be a curable disease. The progression of my condition led to a desperate two-year period of being bedridden. I found myself in a frail body, unable to move my arms or legs due to muscle damage. It was a time when even the simplest task required the assistance of six people. Machines breathed for me, and my voice was reduced to a growling mumble through a tracheostomy. The significant maintenance expenses became a barrier for my mother to continue working. They were huge, and my mother could not even go to work to pay those costs. Of all the worries, she died thereafter soon. Ultimately, the immense stress proved to be too much, resulting in her passing and leaving me in sorrow.
The pivotal moment in my journey came when a dedicated nurse questioned the initial diagnosis. Extensive tests followed, and I was diagnosed with Pompe’s disease, a rare condition causing skeletal muscle weakness. Since 2016, my life has revolved around a unique treatment plan administered every two weeks, a process that demands resilience and patience.
Coping with Pompe disease entails a lifelong commitment to treatment while confronting a challenging prognosis. Treatment sessions, lasting 4-5 hours, can be physically draining, leading to fatigue, headaches, and a noticeable loss of energy. As with any chronic condition, persistent pain becomes a constant companion in daily life. Despite the usual slim build associated with my condition, I stand 189 cm and weigh 130 kg due to a slow metabolism. Bound to a wheelchair, I can’t walk on my own, but I am determined to continue to work on maintaining movement and strength. Still, I am incredibly thankful for getting this treatment; without it, people like me wouldn’t last long.
My perspective of life, death, and the absence of a higher power has evolved through years of facing unimaginable challenges. Amidst the challenges, I find joy in small victories and the unwavering support of loved ones. My work at an enterprise providing TV and internet services is not just a job but a commitment to contribute and find fulfillment despite my physical limitations. I count myself fortunate to have a wonderful wife who sees beyond the physical body. She sees the goodness in me, and her smile is my source of happiness. Reflecting on my extraordinary journey, I harbor no regrets. To those on the brink of losing hope, my message is simple – giving up is okay, but every new day brings a chance for change. Through tears and self-reflection, I pressed on, finding strength in the curiosity of what the next day would bring.
My story bears witness to the strength of resilience, the importance of kindness, and the potential for positive change, even in the face of seemingly insurmountable challenges. It’s a journey that exemplifies the triumph of the human spirit and serves as a beacon of hope for those facing their own struggles.
															This Material was created with support of Swixx Biopharma.
															Testimonial represents the sole standpoint of the storyteller.
															For any advice about treatment, patients must refer to their treating physician.
															NM-CH-2024-2-421; Approval date: February 2024														
I’m Mariliis, a 35-year-old woman from Estonia and the only known woman in the country with Gaucher's disease. As I share my story, it’s a glimpse into my life – how I have faced challenges, found strength, and embraced motherhood despite living with this uncommon condition.
Gaucher disease is a rare genetic metabolic disorder typically involving the spleen, liver, and bone. It is a complex condition with a wide range of symptoms and severity, and unfortunately, it is not always easy to diagnose. Luckily, I was diagnosed early, at the age of 6. I had nose bleeding, and I lived with persistent pain in my stomach, and my spleen became very big. My blood test results confirmed there was a problem.
Timely and continuous treatment is the recipe for life. Without treatment, the condition deteriorates, and pain and bleeding will be persistent. Reflecting on a period when I temporarily paused treatment during a year-long adventure in Australia, I recall the significant setback I faced upon returning to Estonia. Due to the climate and sun, I had never felt more energetic in my life than there; towards the end, I started to feel that something was wrong. It served as a stark reminder of the vital role consistent treatment plays, as Gaucher cells had spread throughout my body, leading to a health collapse. It was the only time in 20 years that the disease affected my life so much; with resumed therapy, all went gradually to normal.
Despite occasional bouts of intercostal neuralgia and monthly waves of fatigue, I maintain a positive outlook. My condition falls on the milder end of the spectrum, and I acknowledge the diversity within the Gaucher community, where each patient may experience the disease uniquely. In my teens, I grappled with depression, yearning for a normal life free from frequent hospital visits. The turning point came when I connected with the Swedish Gaucher Alliance, discovering a supportive community that understood my journey. This newfound circle of friends became my “Gaucher family,” dispelling my sense of isolation and lifting me out of depression.
Initially, my dream of becoming a mother encountered uncertainties. Early advice recommended abandoning thoughts of having children. However, as treatment progressed, I discovered that motherhood was indeed possible. I needed to comprehend the potential risks to my future children. Through careful preparation, consultations with doctors, and ongoing treatment, I successfully welcomed three children into my life, finding immense joy in their presence.
As a mother, I have faced unique challenges. My wrist weakness prevents me from carrying my children as much as I might like, but this limitation has fostered independence in them. Despite the adjustments, I radiate happiness and contentment in my role as a mother.
After my treatment regimen was changed to oral therapy several months ago, life became much easier for me and my family. I am not sure how would have coped with a twice-a-month infusion, as I was doing for all those previous years. Although, I understand how lucky we are that Gaucher disease has the treatment. In my journey, you find a remarkable story of triumph over adversity, a celebration of the strength found in supportive communities, and the fulfillment of a dream to create a loving family despite the challenges posed by Gaucher’s disease.
															This Material was created with support of Swixx Biopharma.
															Testimonial represents the sole standpoint of the storyteller.
															For any advice about treatment, patients must refer to their treating physician.
															NM-CH-2024-2-422; Approval date: February 2024														
															This Material was created with support of Swixx Biopharma.
															Testimonial represents the sole standpoint of the storyteller.
															For any advice about treatment, patients must refer to their treating physician.
															NM-CH-2024-2-723; Approval date: February 2024
														
															This Material was created with support of Swixx Biopharma.
															Testimonial represents the sole standpoint of the storyteller.
															For any advice about treatment, patients must refer to their treating physician.
															NM-CH-2024-2-666; Approval date: February 2024
														
															This Material was created with support of Swixx Biopharma.
															Testimonial represents the sole standpoint of the storyteller.
															For any advice about treatment, patients must refer to their treating physician.
															NM-CH-2024-2-859; Approval date: February 2024
NM-CH-2024-2-860; Approval date: February 2024
														
															This Material was created with support of Swixx Biopharma.
															Testimonial represents the sole standpoint of the storyteller.
															For any advice about treatment, patients must refer to their treating physician.
															NM-CH-2024-5-2989; Approval date: May 2024														
															This Material was created with support of Swixx Biopharma.
															Testimonial represents the sole standpoint of the storyteller.
															For any advice about treatment, patients must refer to their treating physician.
															NM-CH-2024-9-4741; Approval date: September 2024
														
															This Material was created with support of Swixx Biopharma.
															Testimonial represents the sole standpoint of the storyteller.
															For any advice about treatment, patients must refer to their treating physician.
															NM-CH-2024-11-7256; Approval date: January 2025
														
															This Material was created with support of Swixx Biopharma.
															Testimonial represents the sole standpoint of the storyteller.
															For any advice about treatment, patients must refer to their treating physician.
															NM-CH-2025-2-808; Approval date: February 2025
														
															This Material was created with support of Swixx Biopharma.
															Testimonial represents the sole standpoint of the storyteller.
															For any advice about treatment, patients must refer to their treating physician.
																													
															This Material was created with support of Swixx Biopharma.
															Testimonial represents the sole standpoint of the storyteller.
															For any advice about treatment, patients must refer to their treating physician.
															NM-CH-2025-8-4876; Approval date: September 2025														
Created in collaboratrion with Epicana z.ú.
Created in collaboratrion with Epicana z.ú.
															This Material was created with support of Swixx Biopharma.
															Testimonial represents the sole standpoint of the storyteller.
															For any advice about treatment, patients must refer to their treating physician.
															NM-CH-2025-9-5278; Approval date: September 2025
														
 
							February 28th, 2025
At Swixx Biopharma, the Rare Diseases therapeutic area has always been at our core, reflecting our commitment to improving the lives of people affected by rare diseases. With nearly twenty innovative therapies from our esteemed partners, including AstraZeneca/Alexion, BioCryst, Ipsen, Jazz Pharmaceuticals, Krystal, Kyowa Kirin, Otsuka, PTC, and Sanofi, Swixx is proud to enable treatment options for numerous rare diseases that continue to be underserved globally.
 
											February 28th, 2025
At Swixx Biopharma, the Rare Diseases therapeutic area has always been at our core, reflecting our commitment to improving the lives of people affected by rare diseases. With nearly twenty innovative therapies from our esteemed partners, including AstraZeneca/Alexion, BioCryst, Ipsen, Jazz Pharmaceuticals, Krystal, Kyowa Kirin, Otsuka, PTC, and Sanofi, Swixx is proud to enable treatment options for numerous rare diseases that continue to be underserved globally.
Irena Hampel Hršak, M.D., Commercial and Marketing Lead Rare Diseases at Swixx Biopharma, explains, “Our role in unlocking access to medicines in areas of unmet need is crucial, bridging the gap between the innovation of our partners and the patients in our markets.” Through our dedication to access, Swixx ensures that groundbreaking therapies are made available to patients who need them most.
As part of our ongoing commitment, we engage with healthcare professionals (HCPs) through scientific discussions aimed at improving patient management and care. This is facilitated by regional webinars and an accessible online platform for HCPs, offering educational content such as web-conferences, videos, patient testimonials, and partner education materials. We also organize local scientific events to foster collaboration and knowledge exchange.
To commemorate Rare Disease Day 2025, we stand in solidarity with the rare disease community by raising awareness and advocating for equity, ensuring that people living with rare disorders can lead fuller, healthier lives. As many continue to be under-heard, under-represented, and under-served, promoting fairness in rare disease care remains our top priority.
Through our engagement with Patient Advocacy Groups (PAGs), we support rare disease advocates across our countries and strengthen patient organizations. We provide capability-building programs through the PAG Academy project, which enhances their ability to support their communities.
Vukašin Andrić, M.D., Medical Lead Rare Disease, emphasizes, “Our commitment to continuous collaboration with the scientific community and patient associations is driven by our ultimate goal of improving patient outcomes in our region.”
This collaboration is key to creating a broader, more effective network of support for patients and their families.
We also run specific awareness campaigns aimed at educating the public and media about rare diseases. These projects raise the visibility of rare conditions, ensuring media representatives are well-informed, while reinforcing the importance of rare diseases in the broader healthcare conversation.
Swixx teams are actively involved in volunteer activities and community-driven projects that can improve rare patient care. Together with our stakeholders, we are committed to supporting initiatives that improve the patient journey across our diverse markets.
At Swixx, we believe in the power of collaboration, advocacy, and access to make a difference in the lives of those living with rare diseases. In a world where, far too often, the rare community is overlooked, we commemorate Rare Disease Day 2025 by reaffirming our commitment to creating a more equitable world for rare disease patients - one where they are heard, represented, and supported in their journey toward better health and a better future.
								Swixx Biopharma AG
								Neuhofstrasse 5A
CH-6340 Baar
Switzerland
	
																		Tel. +41 41 5523 440
																info@swixxbiopharma.com
								
							
								
								Hybernská 5, 11000 Praha 1
								Czech Republic
								Tel. +420 242 434 242
								info@swixxbiopharma.com